CEF Control Peptide Pool - 8 mg
- Cat.Number : AS-61036-025
- Manufacturer Ref. :
-
Availability :
In production
Alternative choices
The CEF Control Peptide Pool is a group of 32 peptides, 8-12 amino acids in length, with sequences derived from the human Cytomegalovirus, Epstein-Barr Virus and Influenza Virus.This product contains 0.25 mg of the 32 CEF peptides for a total of 8 mg in one vial. Used in the stimulation of IFNg release from CD8+ T cells in individuals with defined HLA types, these epitopes are useful in applications such as ELISPOT, intracellular cytokine and CTL assays.
Specifications
Modification | |
Conjugation |
|
---|---|
Quantity & Purity | |
Purity |
|
Storage & stability | |
Form |
|
Storage Conditions |
|
Activity | |
Application | |
Biomarker Target | |
Research Area | |
Sub-category Research Area | |
Usage |
|
Source | |
Source / Species |
|
Downloads
You may also be interested in the following product(s)
Citations
Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.
J Hematol Oncol . 2017 Apr 07 ; 10(1) 82 | DOI : 10.1186/s13045-017-0459-2.
- S. Mehrotra
Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo.
PLoS Pathog . 2017 Feb 24 ; 13(2) e1006232 | DOI : 10.1371/journal.ppat.1006232.
- N. Bhattarai
Cryopreservation of Human Mucosal Leukocytes.
PLoS One . 2016 May 27 ; 11(5) e0156293 | DOI : 10.1371/journal.pone.0156293.
- SM. Hughes
Change in CD3ζ-chain expression is an independent predictor of disease status in head and neck cancer patients.
Int J Cancer . 2016 Mar 08 ; 139(1) 122 | DOI : 10.1002/ijc.30046.
- D. Upreti
Sprouty-2 regulates HIV-specific T cell polyfunctionality.
J Clin Invest . 2014 Jan 01 ; 124(1) 198 | DOI : 10.1172/JC170510.
- YL. Chiu
Memory phenotypes of HIV-specific CD8+ T cell responses are independent of functional activity as defined by cytokine output.
Open J Immunol . 2014 Sep 01 ; 4(3) 83 | DOI : 10.4236/oji.2014.43012.
- ME. Richmond
Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+ T cells targeting AMA1 class I epitopes.
PloS One . 2014 Sep 11 ; 9(9) e106241 | DOI : 10.1371/journal.pone.0106241.
- M. Sedegah
Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15–dependent DC crosstalk.
J Immunol . 2014 Jul 30 ; 93(5) 2297 | DOI : 10.4049/jimmunol.1400489.
- K. Sehgal
Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer.
Clin Cancer Res . 2013 Dec 09 ; 20(5) 1125 | DOI : 10.1158/1078-0432.CCR-13-2147
- DA. Wick
T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity.
Breast Cancer Res Treatment . 2013 Jun 08 ; 139(3) 657 | DOI : 10.1007/s10549-013-2577-z
- DL. Cecil
SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer.
Oncoimmunol . 2013 Jun 10 ; 2(7) e25205 | DOI : 10.4161/onci.25205.
- KM. Dhodapkar
Transcutaneous immunization of healthy volunteers with an attenuated Listeria monocytogenes vaccine strain and cholera toxin adjuvant.
Vaccine . 2013 May 22 ; 31(32) 3257 | DOI : 10.1016/j.vaccine.2013.05.028
- EH. Eypper
Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP).
Malaria J . 2013 Jun 05 ; 12 185 | DOI : 10.1186/1475-2875-12-185
- M. Sedegah
T-cell responses to hepatitis B splice-generated protein of hepatitis B virus and inflammatory cytokines/chemokines in chronic hepatitis B patients. ANRS study: HB EP 02 HBSP-FIBRO.
J Viral Hepatitis . 2012 Apr 19 ; 19(12) 872 | DOI : 10.1111/j.1365-2893.2012.01611.x.
- F. Bayard
A Poxvirus vaccine is safe, induces T-Cell responses, and decreases viral load in patients with chronic Hepatitis C.
Gastroenterol . 2011 Jun 13 ; 141(3) 890 | DOI : 10.1053/j.gastro.2011.06.009
- F. Habersetzer
Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11.
Cellular Immunol . 2011 Apr 23 ; 270(1) 62 | DOI : 10.1016/j.cellimm.2011.04.005
- M. Matijevic
Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function.
J Transl Med . 2011 Mar 08 ; 9 26 | DOI : 10.1186/1479-5876-9-26
- WC. Olson
An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies.
J Immunol Methods . 2010 Jul 15 ; 360(1-2) 149 | DOI : 10.1016/j.jim.2010.07.003
- JS. Nielsen
Measuring T-cell immunity in HIV vaccine clinical trials: PBMC and ELISPOT assay proficiency concordance in laboratories from 3 continents.
Clin Vaccine Immunol . 2008 Dec 17 ; | DOI : 10.1128/CVI.00326-08.
- M. Boaz
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection.
J Exp Med . 2008 Nov 10 ; 205(12) 2763 | DOI : 10.1084/jem.20081398.
- RB. Jones
Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials.
J Immunol Methods . 2007 Feb 28 ; 322(1-2) 57 | DOI : 10.1016/j.jim.2007.02.003
- M. Bull
Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials.
J Immunol Methods . 2006 Aug 15 ; 315(1-2) 121 | DOI : 10.1016/j.jim.2006.07.015
- Z. Moodie
References
Epitope mapping of HIV-specific CD8+ T cell responses by multiple immunological readouts reveals distinct specificities defined by function.
J Virol . 2010 Nov 17 ; 85(3) 1275 | DOI : 10.1128/JVI.01707-10.
- ME. Richmond
A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays
J Immunol Methods . 2002 Feb 01 ; 260(1-2) 157 | DOI : https://doi.org/10.1016/S0022-1759(01)00535-X
- JR. Currier
- et al
Design and Validation of an Enzyme-Linked Immunospot Assay for Use in Clinical Trials of Candidate HIV Vaccines
AIDS Res Hum Retroviruses . 2002 Jun 01 ; 18(9) 611 | DOI : https://doi.org/10.1089/088922202760019301
- M. Mwau
- et al